Marker Therapeutics - MRKR Competitors

Orgenesis (NASDAQ:ORGS) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Which has higher valuation and earnings, ORGS or MRKR?

Orgenesis has higher revenue and earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$35.50 million	1.31	-$18.05 million	$0.17	11.00
Marker Therapeutics	$1.24 million	26.93	-$41.88 million	-$0.50	-0.80

Is ORGS or MRKR more profitable?

Orgenesis has a net margin of 11.76% compared to Marker Therapeutics' net margin of 0.00%. Orgenesis' return on equity of 9.02% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	11.76%	9.02%	5.85%
Marker Therapeutics	N/A	-97.35%	-62.97%

Do institutionals and insiders hold more shares of ORGS or MRKR?

15.2% of Orgenesis shares are held by institutional investors. Comparatively, 31.8% of Marker Therapeutics shares are held by institutional investors. 7.7% of Orgenesis shares are held by insiders. Comparatively, 27.2% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the MarketBeat Community prefer ORGS or MRKR?

Marker Therapeutics received 70 more outperform votes than Orgenesis when rated by MarketBeat users.

Company	Underperform	Outperform
Orgenesis	N/A	N/A
Marker Therapeutics	Outperform Votes 70 63.06%	Underperform Votes 41 36.94%

Which has more risk & volatility, ORGS or MRKR?

Orgenesis has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500.

Does the media refer more to ORGS or MRKR?

In the previous week, Marker Therapeutics had 3 more articles in the media than Orgenesis. MarketBeat recorded 7 mentions for Marker Therapeutics and 4 mentions for Orgenesis. Orgenesis' average media sentiment score of 1.88 beat Marker Therapeutics' score of 1.32 indicating that Orgenesis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orgenesis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Marker Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Do analysts prefer ORGS or MRKR?

Marker Therapeutics has a consensus price target of $1.25, suggesting a potential upside of 212.97%. Given Marker Therapeutics' higher possible upside, analysts plainly believe Marker Therapeutics is more favorable than Orgenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Marker Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Orgenesis beats Marker Therapeutics on 8 of the 15 factors compared between the two stocks.